-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Eli Lilly (Eli Lilly and Company) announced that the US FDA has approved the CDK4/6 inhibitor Verzenio (abemaciclib) for extended indications, combined with endocrine therapy (tamoxifen or aromatase inhibitors), and adjuvant treatment of hormone receptors.
Breast cancer has surpassed lung cancer as the most common cancer in the world, with approximately 2.
This approval is based on an open-label, phase 3 clinical trial of patient subgroup analysis results
The analysis of this patient subgroup showed that Verzenio combined with endocrine therapy reduced the risk of relapse by approximately 36% compared with endocrine therapy alone (HR=0.
Verzenio (abemaciclib) is a CDK4/6 inhibitor
Reference materials:
[1] FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer.
(The original text has been deleted)